Newsfeeds - Spark Newswire

2 minute read

SOL Global Reduces Principal Amount Of Credit Facility From $50M To $4.52M, Announces Management Changes

Today, 7:33 AM

SOL Global Investments Corp. (OTC: SOLCF) announced that it is up to date on all interest payments and has repaid an additional $1.0 million towards its $50 million credit facility with an arm's length lender, reducing the principal amount of the credit facility to $4.52 million.

CSE:SOL

2 minute read

Skye Receives Positive Safety Review Of Cannabinoid Based Drug For Treatment Of Glaucoma After Second Cohort Of Phase 1 Study

By Vuk Zdinjak

Today, 7:33 AM

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has received a positive recommendation following a pre-specified data review by the safety review committee ("SRC") based on dosing of the sec

SKYE

3 minute read

Key Marijuana Executive Changes: Who Will Lead MariMed After CEO’s Passing? MJBiz CEO Steps Down

By Jelena Martinovic

Today, 7:33 AM

MJBiz CEO To Step Down Marijuana Business Daily's Chris Walsh will step down as CEO in January.

BAYRY

2 minute read

Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma

By Vuk Zdinjak

Today, 7:33 AM

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial of SBI-100 Ophthalmic Emulsion.

SKYE

2 minute read

Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma

By Vuk Zdinjak

Today, 7:33 AM

Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has completed the production of SBI-100 Ophthalmic Emulsion (&ld

SKYE

3 minute read

These OTC Securities Had the Most Trading Activity in June

Today, 7:33 AM

Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as volumes in crypto and cannabis slowed.

ADRNY

1 minute read

Watch CV Sciences & Lyphe Group At The Benzinga Cannabis Hour

By Jose Rodrigo Safdiye

Today, 7:33 AM

Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday’s show, hosts Elliot Lane and Patrick Lane invited Joseph Dowling, CEO of CV Sciences (OTC: CVSI) and Dean Friday CEO & Co-Founder of Lyphe Group

CVSI